SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

A roundup of the most newsworthy healthcare press releases from PR Newswire, including FDA approval for Aktiia's cuffless ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug ...

Ionis Pharmaceuticals IONS reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, the ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...